Related Experiment Videos
Aggressive behavior in Huntington's disease: treatment with propranolol
The Journal of Clinical Psychiatry
|March 1, 1987
Summary
Propranolol effectively reduced aggression in Huntington's disease patients resistant to other treatments. This beta-blocker offers a new therapeutic avenue for managing behavioral symptoms in advanced stages of this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- Aggressive behaviors are common and challenging symptoms in advanced HD.
- Neuroleptic medications are often ineffective for managing these behavioral disturbances.
Observation:
- Three patients with advanced Huntington's disease exhibited severe episodic aggressive behavior.
- These patients did not respond adequately to neuroleptic treatments.
- A careful titration of propranolol dosage was initiated.
Findings:
- Propranolol administration led to a significant reduction in aggressive episodes across all three patients.
- Optimal therapeutic dosages varied, with 180 mg/day for one patient and 30 mg/day for the other two.
- The beta-blocker propranolol demonstrated efficacy in managing treatment-resistant aggression in HD.
Implications:
- Propranolol may be a valuable therapeutic option for managing aggression in Huntington's disease.
- Further research is warranted to confirm these findings in larger cohorts.
- This suggests a potential role for beta-blockers in the symptomatic treatment of advanced neurodegenerative conditions.